PMID- 36089339
OWN - NLM
STAT- MEDLINE
DCOM- 20230131
LR  - 20230202
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 70
IP  - 1
DP  - 2023 Jan 30
TI  - Association of continuous positive airway pressure therapy on cardiac hypertrophy 
      in patients with sleep apnea comorbid with type 2 diabetes mellitus.
PG  - 47-58
LID - 10.1507/endocrj.EJ22-0308 [doi]
AB  - Previous reports indicated the therapeutic effect of chronic continuous positive 
      airway pressure (CPAP) therapy on cardiac hypertrophy due to sleep apnea 
      syndrome. However, little is known for cases involving diabetic complications. 
      This retrospective observational study examined the effects of CPAP therapy on 
      left ventricular hypertrophy (LVH) in patients with obstructive sleep apnea 
      syndrome (OSAS) and type 2 diabetes mellitus (T2DM). For all cases, the 
      observation period was 3 years from the time when the patient was introduced to 
      CPAP therapy. Overall, 123 patients were divided into a good CPAP group (CPAP >/=4 
      h/day, n = 63) and non-adherence group (CPAP <4 h/day, n = 60). The mean CPAP 
      usage times were 5.58 +/- 1.23 and 1.03 +/- 1.17 h/day in the good CPAP and 
      non-adherence groups, respectively. Regression tendencies of the thickness of the 
      left ventricular posterior (-0.30 +/- 1.19 mm) and interventricular septal walls 
      (-0.48 +/- 1.22 mm) were observed in the good CPAP group. Hypertrophic tendencies 
      of the left ventricular posterior wall (+0.59 +/- 1.44 mm) and interventricular 
      septal wall thickness (+0.59 +/- 1.43) were observed in the non-adherence group. 
      Left ventricular posterior wall thickness (coefficient: -0.254, p = 0.0376) and 
      interventricular septal wall thickness (coefficient: -0.426, p = 0.0006) were 
      more likely to be greater in the non-adherence group than in the good CPAP group. 
      Patients in the non-adherence group with an apnea hypopnea index >/=30 had 
      increased left ventricular posterior wall thickness (coefficient: -0.263, p = 
      0.0673) and interventricular septal wall thickness (coefficient: -0.450, p = 
      0.0011). In conclusion, appropriate CPAP therapy is an effective treatment for 
      LVH in patients with T2DM and OSAS, especially for severe cases.
FAU - Ohira, Akeo
AU  - Ohira A
AD  - Department of Endocrinology and Diabetes, Yokohama City University Medical 
      Center, Yokohama 232-0024, Japan.
FAU - Yamakawa, Tadashi
AU  - Yamakawa T
AD  - Department of Endocrinology and Diabetes, Yokohama City University Medical 
      Center, Yokohama 232-0024, Japan.
FAU - Iwahashi, Noriaki
AU  - Iwahashi N
AD  - Division of Cardiology, Yokohama City University Medical Center, Yokohama 
      232-0024, Japan.
FAU - Tanaka, Shunichi
AU  - Tanaka S
AD  - Kanazawa Medical Clinic, Yokohama 220-0012, Japan.
FAU - Sugiyama, Mai
AU  - Sugiyama M
AD  - Department of Endocrinology and Diabetes, Yokohama City University Medical 
      Center, Yokohama 232-0024, Japan.
FAU - Harada, Marina
AU  - Harada M
AD  - Department of Endocrinology and Diabetes, Yokohama City University Medical 
      Center, Yokohama 232-0024, Japan.
FAU - Ichikawa, Masahiro
AU  - Ichikawa M
AD  - Department of Endocrinology and Diabetes, Yokohama City University Medical 
      Center, Yokohama 232-0024, Japan.
FAU - Akiyama, Tomoaki
AU  - Akiyama T
AD  - Department of Endocrinology and Diabetes, Yokohama City University Medical 
      Center, Yokohama 232-0024, Japan.
FAU - Orime, Kazuki
AU  - Orime K
AD  - Department of Endocrinology and Diabetes, Yokohama City University Medical 
      Center, Yokohama 232-0024, Japan.
FAU - Terauchi, Yasuo
AU  - Terauchi Y
AD  - Department of Endocrinology and Metabolism, Yokohama City University School of 
      Medicine, Yokohama 236-0004, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220910
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
SB  - IM
MH  - Humans
MH  - Continuous Positive Airway Pressure
MH  - *Diabetes Mellitus, Type 2/complications/therapy
MH  - *Sleep Apnea Syndromes/complications
MH  - *Sleep Apnea, Obstructive/complications/therapy
MH  - Cardiomegaly/complications
MH  - Hypertrophy, Left Ventricular/complications/epidemiology
OTO - NOTNLM
OT  - Left ventricular hypertrophy (LVH)
OT  - Obstructive sleep apnea syndrome (OSAS)
OT  - Type 2 diabetes (T2D)
EDAT- 2022/09/12 06:00
MHDA- 2023/02/01 06:00
CRDT- 2022/09/11 21:52
PHST- 2022/09/12 06:00 [pubmed]
PHST- 2023/02/01 06:00 [medline]
PHST- 2022/09/11 21:52 [entrez]
AID - 10.1507/endocrj.EJ22-0308 [doi]
PST - ppublish
SO  - Endocr J. 2023 Jan 30;70(1):47-58. doi: 10.1507/endocrj.EJ22-0308. Epub 2022 Sep 
      10.